百草枯SL20制剂中催吐剂PP796有效性的证据——已发表与未发表证据的叙述性综述
该叙述性综述检索PubMed、Google及美国知情权网站的公司文件,评估百草枯SL20制剂中催吐剂PP796的有效性。临床前犬和猴研究显示PP796致吐EC50约为0.5-2 mg/kg,剂量增至0.5-20 mg/kg范围可加快首次呕吐并减少百草枯吸收;但SL20制剂选用的0.5 g/L(0.05%)浓度仅基于1970年代初一项5名志愿者(仅2人实际呕吐)的II期研究和37例患者数据。1980年代英国毒物监测研究仅21例可评估呕吐时间,其中11例(52.4%,95%CI 31-73.7%)在30分钟内呕吐,未发现对死亡率的影响。作者认为0.05%PP796催吐证据薄弱或未发表,无临床获益或降低死亡证据,不支持FAO/WHO联席会议强制添加催吐剂的规定。
要点
- 百草枯SL20中PP796浓度为0.5 g/L(0.05%),相当于70 kg成人摄入10 mL最低致死量时0.071 mg/kg,目标为30分钟内诱导早期呕吐。
- 临床前犬和猴研究显示PP796致吐EC50约为0.5-2 mg/kg,有效剂量范围为0.5-20 mg/kg,剂量增加可加快首次呕吐并减少0-24小时血浆AUC达100倍(与未加PP796对照组相比)。
- SL20制剂所选0.05%浓度仅基于1970年代初一项5名志愿者(仅2人实际呕吐)的II期研究,辅以37例患者服用2 mg的临床试验数据。
- 1980年代英国强制毒物监测研究中,仅21例摄入含PP796百草枯SL20的患者有呕吐时间数据,其中11例(52.4%,95%CI 31-73.7%)在30分钟内呕吐。
- 任何关于含0.05%PP796的百草枯SL制剂的研究均未发现对死亡率的影响;作者认为无证据支持FAO/WHO联席会议强制在百草枯产品中添加PP796或其他催吐剂。
适用人群与场景
- 摄入百草枯SL20制剂(含0.05% PP796)的患者,包括临床前犬和猴研究及临床志愿者、患者研究。
- 斯里兰卡临床研究纳入摄入Gramoxone® Inteon(含三倍更高PP796、MgSO4和海藻酸盐的修订制剂)达100 mL的患者。
处置流程与药物剂量
- 百草枯SL20制剂中添加PP796浓度为0.5 g/L或0.05%(相当于70 kg成人摄入最低致死量10 mL时0.071 mg/kg),目的是在30分钟内诱导早期呕吐、减少百草枯从肠道吸收并预防死亡。
- 该浓度由FAO农药专家委员会(现FAO/WHO农药规格联席会议的前身)强制要求。
研究设计与关键结果
- 临床前犬和猴研究显示PP796致吐EC50约为0.5-2 mg/kg;进一步增加PP796浓度可加快首次呕吐时间,并使0-24小时血浆AUC较未加PP796对照组减少100倍。
- SL20制剂所选0.5 g/L(0.05%)浓度仅基于1970年代初一项II期研究(5名志愿者接受3种不同剂量,仅2人实际呕吐),辅以37例患者服用2 mg的临床试验数据。
- 1980年代英国强制毒物监测研究中,仅21例摄入含PP796百草枯SL20的患者有呕吐时间数据,其中11例(52.4%,95%CI 31-73.7%)在30分钟内呕吐。
- 任何关于含0.05%PP796的百草枯SL制剂的研究均未发现对死亡率的影响。
- 斯里兰卡一项在催吐剂首次引入30年后进行的临床研究显示,修订制剂Gramoxone® Inteon(PP796浓度高3倍,并含MgSO4和海藻酸盐)可提高早期呕吐率,并对摄入量达100 mL的患者轻度降低死亡率。
证据类型、等级与局限
- 证据类型:叙述性综述,汇总已发表文献和未发表的公司报告(临床前犬和猴研究、II期志愿者研究、毒物监测研究、临床研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于一项不充分的II期研究选择了过低的PP796浓度(0.05%)用于百草枯制剂。
- 作者认为,目前0.05%PP796在百草枯SL20中加快摄入后呕吐的证据薄弱或未发表,未发现临床获益或降低死亡的证据。
- 作者认为,没有证据支持FAO/WHO农药规格联席会议强制在百草枯产品中添加PP796或其他催吐剂。
- 作者认为,已开发出更高催吐剂浓度的产品但未广泛使用,这些产品可能预防死亡。
指南或共识出处
- Food and Agriculture Organization Committee of Experts on Pesticides in Agriculture(现FAO/WHO Joint Meeting on Pesticide Specifications)关于百草枯产品中添加催吐剂的规定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The bipyridyl herbicide paraquat was first introduced into agriculture in the 1960s by Imperial Chemical Industries. Due to issues with unintentional poisoning, the centrally acting emetic PP796 was added in 1976 to the company's 20% paraquat ion soluble liquid (SL20) formulations (Gramoxone®) at a concentration of 0.5 g/L or 0.05% (equivalent to 0.071 mg/kg in a 70 kg adult ingesting a minimum lethal dose of 10 mL) to induce early vomiting (within 30 min), reduce paraquat absorption from the gut, and prevent deaths. Its presence in paraquat products was subsequently mandated by the Food and Agriculture Organization Committee of Experts on Pesticides in Agriculture (predecessor to the current FAO/WHO Joint Meeting on Pesticide Specifications). However, no primary pre-clinical or clinical data have been published regarding the effectiveness of PP796. We reviewed the published literature and unpublished company reports for data on the effectiveness of PP796.
METHODS: PubMed and Google were searched for published studies on the emetic using the search terms "paraquat" and ["emetic" or "PP796"]. Company documents reporting pre-clinical and clinical studies were accessed at the website of U.S. Right to Know (https://usrtk.org/pesticides/paraquat-papers/). Primary study reports were sought as well as overviews written by company toxicologists.
RESULTS: Pre-clinical dog and monkey studies indicated that the PP796 EC50 dose for vomiting was around 0.5-2 mg/kg. Further increasing the PP796 concentration speeded up the time to first vomit and reduced the amount of paraquat absorbed (as assessed by the 0-24 h plasma area-under-the-curve) 100-fold compared to a control group receiving no PP796. However, the dose selected for paraquat SL20 formulations by the company (0.5 g/L or 0.05%) was based exclusively on a phase II study in the early 1970s involving five volunteers receiving 3 different doses, with only two individuals actually vomiting, supplemented by data from 37 patients taking 2 mg in clinical trials. A UK-mandated toxicovigilance study in the 1980s identified only 21 patients ingesting paraquat SL20 with PP796 for whom data on time to vomit was available; of these patients, 11 vomited within 30 min (52.4%, 95%CI 31-73.7%). No effect on mortality could be identified from any study of paraquat SL containing 0.05% PP796. A clinical study in Sri Lanka 30 years after the emetic was first introduced, of a revised formulation (Gramoxone® Inteon) containing a three-fold higher amount of PP796, as well as MgSO4 and an alginate, showed increased rates of early vomiting and modestly reduced mortality for patients ingesting up to 100 mL.
CONCLUSION: Pre-clinical studies showed a clear dose response for PP796 to cause early vomiting, with effective doses in the 0.5-20 mg/kg range. A too low concentration of PP796 was selected for paraquat formulations based on an inadequate phase II study. Currently, evidence that PP796 at 0.05% in paraquat SL20 causes more rapid vomiting after ingestion is weak or unpublished; no evidence of clinical benefit or fewer deaths has been identified. There is no evidence to support the FAO/WHO Joint Meeting on Pesticide Specifications mandate to include PP796 or any other emetic in paraquat products. Products with higher emetic concentrations have been developed but are not widely used; it is possible they may prevent deaths.
参考来源
- Eddleston M. Evidence for the efficacy of the emetic PP796 in paraquat SL20 formulations - a narrative review of published and unpublished evidence. Clin Toxicol (Phila). 2022. PMID: 35950791. doi:10.1080/15563650.2022.2105709
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。